Krystal Biotech, Inc.

Krystal Biotech, Inc. Earnings Recaps

KRYS Health Care 1 recap
Q3 2025 Nov 5, 2025

Krystal Biotech delivered a strong Q3 2025, with VYJUVEK revenues reaching $97.8 million, bolstered by recent expansions in Europe and Japan. The company is well-positioned for sustained growth with an expanding prescriber base and new clinical programs underway.

Key takeaways
  • VYJUVEK revenues total $97.8 million for Q3, contributing to over $623 million since the product’s launch.
  • Gross margins remained robust at 96%, with an acceleration in over 40 new reimbursement approvals in the U.S. since the last earnings call.
  • Successful launches of VYJUVEK in Germany, France, and Japan are set to enhance patient access and treatment availability.
  • The updated U.S. label for VYJUVEK now includes patients from birth, optimizing the product's market position and potential for higher compliance.
  • Initiation of a new clinical program for Hailey-Hailey disease reinforces Krystal’s commitment to rare disease treatments and expands their innovative pipeline.
Full recap